ERBB2 and breast carcinoma: That study revealed that patients treated for advanced and recurrent breast cancers responded well to HER-2- and AKT1-directed therapy [23], suggesting that the mutation-directed targeted treatment of residual tumor cells improves survival in patients with early-stage breast cancer after NAC and adjuvant chemotherapy or during ET.